Life Sciences and Biotech

Life sciences is the one field where patent law has its own custom-built statute. The Hatch-Waxman Act of 1984 wired FDA drug approval directly into the patent system, creating a regime where a generic company can be sued for infringement before it has sold a single pill, and where the brand can get years of patent term back to compensate for time lost inside the FDA. The biologics equivalent, the BPCIA of 2009, enacted in 2010 as part of the Affordable Care Act, does something similar with a more elaborate and more private choreography.

Understanding biotech patents means holding two separate things at once: the eligibility question of what in biology can be patented at all, which the Supreme Court narrowed sharply in Mayo and Myriad, and the procedural question of how those patents get fought over, which is almost entirely a creature of the Food, Drug, and Cosmetic Act rather than Title 35.

What Hatch-Waxman actually traded

Formally the Drug Price Competition and Patent Term Restoration Act, the 1984 statute was a bargain between two industries. Generics got the Abbreviated New Drug Application under 21 U.S.C. § 355(j), letting them skip duplicative clinical trials and instead show bioequivalence to the approved brand drug. They also got the research safe harbor of 35 U.S.C. § 271(e)(1), which makes it non-infringing to use a patented invention to generate data for FDA submission. Before that safe harbor, a generic could not lawfully begin its development work until the patent expired, which handed the brand a de facto extension.

Brands got two things back. Patent term restoration under 35 U.S.C. § 156 returns time consumed by regulatory review, capped at five years and at fourteen years of effective post-approval life. And they got regulatory exclusivities that run independently of any patent: five years for a new chemical entity, three years for a new clinical investigation supporting a change to an approved drug, seven years for orphan designation, and six months added on for qualifying pediatric studies. An exclusivity is not a patent. It cannot be invalidated, it does not depend on inventing anything, and it blocks FDA from accepting or approving a competitor’s application regardless of what the patent landscape looks like.

The Orange Book and Paragraph IV

The brand lists patents it believes cover the approved drug in FDA’s publication Approved Drug Products with Therapeutic Equivalence Evaluations, universally called the Orange Book. Only certain categories belong there: drug substance, drug product, and approved method-of-use patents. Manufacturing process patents do not. Improper listing has become its own litigation front, and in 2024 the Federal Circuit held in Teva v. Amneal that device patents on an inhaler could not be listed merely because the device holds the drug.

A generic filing an ANDA must certify to each listed patent. Paragraph I and II certifications say no patent is listed or it has expired. Paragraph III says the generic will wait for expiry. Paragraph IV says the patent is invalid, unenforceable, or not infringed, and it is where the litigation lives.

The mechanism is deliberately artificial. Under 35 U.S.C. § 271(e)(2), submitting an ANDA with a Paragraph IV certification is itself defined as an act of infringement. That fiction exists purely to create a case or controversy, so the parties can litigate patent validity on a clean record years before commercial launch instead of after a generic has flooded the market and damages have become catastrophic.

The 30-month stay and the 180-day prize

The generic must notify the brand of its Paragraph IV certification. If the brand sues within 45 days, FDA is barred from granting final approval for 30 months from the notice date, unless a court decides the patent is invalid or not infringed first, or the patent expires. This is the 30-month stay, and its defining feature is that it is automatic. Nobody makes a preliminary injunction showing. Nobody posts a bond. The brand simply files suit and the clock starts.

Balancing that is the 180-day exclusivity awarded to the first generic applicant to file a substantially complete ANDA with a Paragraph IV certification. For six months, FDA will not approve a subsequent generic. That window is the entire economic engine of generic patent challenges, since it is typically the only period in which a generic sells at anything but commodity margins. Congress added forfeiture provisions in 2003 after brands and first filers learned to park the exclusivity in place through settlement, blocking everyone behind them. Reverse-payment settlements of that kind became antitrust-reviewable under FTC v. Actavis (2013), which rejected both a per se rule and near-automatic legality in favor of rule-of-reason analysis.

Biologics and the patent dance

Biologics, meaning large molecules produced in living systems, do not fit the bioequivalence model. The Biologics Price Competition and Innovation Act of 2009, signed into law on March 23, 2010, built a parallel path at 42 U.S.C. § 262(k) for biosimilars, plus a higher tier of interchangeability for products that can be substituted at the pharmacy counter without prescriber involvement.

The patent provisions at 42 U.S.C. § 262(l) are known as the patent dance: a staged, confidential exchange in which the biosimilar applicant shares its application with the reference sponsor, the parties trade contentions, and they negotiate which patents get litigated in a first wave. There is no Orange Book for biologics and no 30-month stay. The reference product gets 12 years of exclusivity from first licensure under § 262(k)(7), with a four-year bar on even filing.

In Sandoz v. Amgen (2017) the Supreme Court held that the information exchange is not enforceable by federal injunction, and that the 180-day notice of commercial marketing may be given before licensure. The practical result is that the dance is largely optional. Declining it has consequences, since the sponsor may then sue immediately on any patent it likes, but it is a choice rather than a command.

What biology can be patented at all

Two Supreme Court decisions redrew the eligibility map under 35 U.S.C. § 101.

Mayo Collaborative Services v. Prometheus Laboratories (2012) invalidated claims to a method of optimizing thiopurine dosing by measuring metabolite levels. The correlation between metabolite concentration and therapeutic effect was a law of nature, and the surrounding steps of administering the drug and measuring the level were routine and conventional. Mayo supplied the two-step framework later generalized to software in Alice, and it has been devastating to diagnostics: a claim that says observe this natural correlation, using ordinary tools, generally fails.

Association for Molecular Pathology v. Myriad Genetics (2013) addressed the BRCA1 and BRCA2 genes. Isolated genomic DNA is not patent eligible, because separating a segment from the chromosome does not change the information it encodes and nature made the sequence. Complementary DNA is eligible, because removing introns produces a molecule that does not occur naturally. The line is synthesis, not effort or expense.

What survives is substantial. Engineered sequences, vectors, recombinant cell lines, antibodies, formulations, purified compounds with markedly different characteristics, and methods of treatment all remain patentable. But Amgen v. Sanofi (2023) tightened § 112 enablement for genus claims, invalidating antibody claims defined by function rather than structure because the specification taught only a screening process rather than the full claimed class. The pressure in biotech has shifted from eligibility toward disclosure.

Frequently asked questions

What is the Hatch-Waxman Act? The Drug Price Competition and Patent Term Restoration Act of 1984, which created the modern generic drug system. It let generic makers rely on the brand’s safety and efficacy data through an Abbreviated New Drug Application, gave brands patent term restoration for time lost to FDA review, and built a litigation channel so patent disputes get resolved before the generic launches rather than after.

What is a Paragraph IV certification? A statement in a generic application that a patent listed in the Orange Book is invalid, unenforceable, or not infringed by the generic product. Filing it is defined as an act of infringement under 35 U.S.C. § 271(e)(2), which manufactures a lawsuit before any drug is sold. If the brand sues within 45 days, FDA approval is stayed for up to 30 months.

What is the 30-month stay? An automatic pause on FDA final approval of a generic, triggered when the brand sues on an Orange Book patent within 45 days of receiving Paragraph IV notice. It runs 30 months from that notice unless the patent expires or a court rules first. It is not an injunction and no one has to prove likelihood of success to get it, which is why critics call it a free litigation hold.

Are gene patents still allowed in the United States? Isolated natural DNA is not patentable after Association for Molecular Pathology v. Myriad Genetics (2013), because merely separating a gene from the genome does not create anything new. Complementary DNA remains eligible because the sequence is not naturally occurring. Engineered constructs, vectors, cell lines, and methods of use can still be patented.

Authorities and sources

• 35 U.S.C. § 271(e): Infringement, ANDA safe harbor and artificial act of infringement (Cornell LII)
• 35 U.S.C. § 156: Extension of patent term (Cornell LII)
• 35 U.S.C. § 101: Inventions patentable (Cornell LII)
• 35 U.S.C. § 112: Specification (Cornell LII)
• 21 U.S.C. § 355: New drugs, including ANDA certifications and exclusivity (Cornell LII)
• 42 U.S.C. § 262: Biological products, including the BPCIA patent provisions (Cornell LII)
• FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
• FDA Purple Book: Licensed biological products database
• Mayo Collaborative Services v. Prometheus Laboratories, 566 U.S. 66 (2012) (Cornell LII)
• Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 576 (2013) (Cornell LII)
• FTC v. Actavis, Inc., 570 U.S. 136 (2013) (Cornell LII)
• Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017) (Cornell LII)
• Amgen Inc. v. Sanofi, 598 U.S. 594 (2023) (Cornell LII)
• USPTO subject matter eligibility guidance

Going further: What Is Patentable? The eligibility test explained .

This page is general legal information, not legal advice, and it does not create an attorney-client relationship.